胰岛素联合治疗的新选择——基础胰岛素+DPP-4抑制剂被引量：3

Basal insulin combined with dipeptidyl peptidase-4 inhibitors

下载PDF

导出

摘要新一代口服降糖药二肽基肽酶-4(dipeptidyl peptidase-4,DPP-4)抑制剂在有效控制血糖的同时能够减轻体重、改善胰岛素抵抗,安全性高,且多为每日1次用药。基础胰岛素的补充在2型糖尿病治疗过程中有重要意义,只需每日1次固定时间注射,并且相比较于预混胰岛素有着更低的低血糖发生率及体重增加。二者联用或可为2型糖尿病的治疗提供一种既有效又安全的治疗模式。本文对近几年二者临床联用各方面的内容作一简单综述。

作者康姚洁王煊

机构地区解放军

出处《药品评价》 CAS 2015年第23期28-32,48,共6页 Drug Evaluation

关键词 2型糖尿病胰岛素 DPP-4抑制剂

分类号 R977.15 [医药卫生—药品]

引文网络
相关文献

参考文献28

1Kretltz A J, Patel MB, Bailey CL New drugs for type 2 diabetes mellitus: what is their place in therapy?[J]. Drugs, 2008, 68(15): 2131-2162.
2Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors[J]. Drugs, 2011, 71(11): 1441-1467.
3Buteau J, EI-Assaad W, Rhodes CJ, et al. Glucagon-like pepfide-1 prevents beta cell glucolipotoxicity[J]. Diabetologia, 2004, 47(5): 806-815.
4曾龙驿.专家专题报告9：控制空腹高血糖，保护胰岛β细胞[J].中华内分泌代谢杂志,2014,30(3):273-274. 被引量：5
5Schreiber SA, Haak T. Insuling glargine benefits patients with type 2 diabetes inadeguately controlled on oral antidabetic treatment: an observati-onal study of everyday practice in 12,216 patients[J]. Diabetes Obes Metab, 2007, 9(1): 31-38.
6成人2型糖尿病胰岛素临床应用中国专家共识[J].药品评价,2012(1):42-44. 被引量：22
7Phung OJ, Scholle JM, Taluar M, et al. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes[J]. JAMA, 2010, 303(14): 1410-1418.
8Monami M, Iacomelli I, Marehionni N, et al. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials[J]. Nutr Metab Cardiovasc Dis, 2010, 20(2): 224-235.
9Monami M, Cremasco F, Lamanna C, et al. Predictors of response to dipeptidyl pcptidase-4 inhibitors: evidence from randomized clinical trials[J]. Diabetes Metab Res Rev, 2011, 27(2): 362-372.
10Scheen AJ, Charpentier G, Ostgren C J, et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus[J]. Diabetes Metab Res Rev, 2010, 26(3): 540-549.

二级参考文献156

1李立明,饶克勤,孔灵芝,姚崇华,向红丁,翟凤英,马冠生,杨晓光,中国居民营养与健康状况调查技术执行组.中国居民2002年营养与健康状况调查[J].中华流行病学杂志,2005,26(7):478-484. 被引量：1783
2毕艳杨黛雅.长效胰岛素类似物对口服降糖药物失效的2型糖尿病患者的有效性和安全性.中华糖尿病杂志,2010,:240-240.
3中华医学会糖尿病学分会.中国2 型糖尿病防治指南(2010 年版)[M].北京:北京大学医学出版社,2011:13.
4Bergman AJ,Cote J,Maes A,et al. Sitagliptin(MK-0431),a selective dipeptidyl-peptidase-IV (DPP-4) inhibitor, does not affect the pharmacokinetics of simvastatin in humans. Clin Pharmacol Ther, 2005,79: 48.
5Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitaglipt in monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract, 2008,79 : 291-298.
6Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabectologia, 2007,50 : 1148-1155.
7Dailey G. New strategies for basal insulin treatment in type 2 diabetes mellitus. Clin Ther, 2004,26 : 889-901.
8Yang WY, Lu J, Weng J,et al. Prevalence of diabetes among men and women in China [ J ]. N Engl J Med, 2010, 362 (12) :1090-1101.
9Funnell MM, Brown TL, Child BP, et al. National standards for diabetes self-management education [ J ]. Diabetes Care, 2011,34( 1 ) :89-96.
10International Diabetes Federation. Diabetes Atlas [ M ]. 4th ed. Brussels, Blgium: International Diabetes Federation, 2009. 376.